ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries

Exhaustive intervention carried out by healthcare non-medical healthcare professionals with the support of community members resulted in a significant reduction of systolic blood pressure, LDL cholesterol levels and CAD risk in patients of Malaysia and Colombia, according to this study presented at ESC 2019 in Paris and simultaneously published in Lancet.

This intervention translated into a 11.4 mmHg reduction of systolic blood pressure and 15.6 mg/dl LDL levels compared against standard protocols.

This intervention ultimately reduced absolute risk of CAD at 10 years in 5 points.

Combining therapies that reduce hypertension and cholesterol, effectively reduce CAD risk, but access to costly medication and adherence to treatment might be poor in those that need them most.


Read also: ESC 2019 | AFIRE: Monotherapy with Rivaroxaban in Atrial Fibrillation and Stable CAD.


Focusing in 30 communities of Colombia and Malaysia, this study aimed at overcoming social barriers for effective management of risk factors in these two developing countries. Multidisciplinary intervention consisted of searching, identifying, treating and controlling risk factors by non-medical staff that visited patients in their homes or in the local healthcare center. Staff tips were clearly aligned with doctor and guideline recommendations.

In addition to advice, the program provided free antihypertensive medication (conversion enzyme inhibitors or angiotensin receptor blockers combined with a diuretic or a calcium blocker) and statins (atorvastatin 20 mg or rosuvastatin 10 mg). The team incorporated a friend or a family member to improve adherence to treatment and lifestyle.

It included a total 1371 hypertensive participants over 50 randomized to intervention with a multidisciplinary team vs. standard treatment.

Primary end point (change in cardiovascular risk at 10 years) was significantly lower in the intervention multidisciplinary arm.

Original title: A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster, randomized controlled trial.

Reference: Schwalm JD et al. Lancet. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...